Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT

  • Yishan Ye
  • , Myriam Labopin
  • , Jia Chen
  • , Depei Wu
  • , Tobias Gedde-Dahl
  • , Didier Blaise
  • , Gérard Socie
  • , Edouard Forcade
  • , Urpu Salmenniemi
  • , Sébastien Maury
  • , Jurjen Versluis
  • , Ali Bazarbachi
  • , Arnon Nagler
  • , Eolia Brissot
  • , Lin Li
  • , Yi Luo
  • , Jimin Shi
  • , Fabio Ciceri
  • , He Huang*
  • , Mohamad Mohty*
  • Norbert Claude Gorin*
*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

7 Citations (Scopus)
16 Downloads (Pure)
Original languageEnglish
Article number85
JournalBlood Cancer Journal
Volume14
Issue number1
DOIs
Publication statusPublished - 27 May 2024

Cite this